Long-term outcomes in patients with BRAF-mutant advanced melanoma: A real-world study

被引：0
|
作者：
Amin, A. [1 ]
Pavlick, A. C. [2 ]
Lee, C. [3 ]
Chou, E. [4 ]
Zhang, Y. [5 ]
Sakkal, L. A. [6 ]
Moser, J. [7 ]
机构：
[1] Levine Canc Inst, Melanoma Immunooncol, Charlotte, NC USA
[2] Weill Cornell Med Ctr, Med Oncol, New York, NY USA
[3] Bristol Myers Squibb, US Hlth Econ & Outcomes Res, Princeton, NJ USA
[4] Bristol Myers Squibb, WW Hlth Econ & Outcomes Res, Princeton, NJ USA
[5] Bristol Myers Squibb, Ctr Observat Res & Data Sci, Princeton, NJ USA
[6] Bristol Myers Squibb, US Med Oncol, Princeton, NJ USA
[7] HonorHlth Res & Innovat Inst, Hematol, Med Oncol, Scottsdale, AZ USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
95P
引用
收藏
页码：S1415 / S1416
页数：2
相关论文
共 50 条
  • [1] Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes
    Schouwenburg, Maartje G.
    Jochems, Anouk
    Leeneman, Brenda
    Franken, Margreet G.
    van den Eertwegh, Alfons J. M.
    Haanen, John B. A. G.
    van Zeijl, Michiel C. T.
    Aarts, Maureen J.
    van Akkooi, Alexander C. J.
    van den Berkmortel, Franchette W. P. J.
    Blokx, Willeke A. M.
    de Groot, Jan Willem B.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Koornstra, Rutger H.
    Kruit, Wim H.
    Louwman, Marieke W. J.
    Piersma, Djura
    van Rijn, Rozemarijn S.
    Suijkerbuijk, Karijn P. M.
    ten Tije, Albert J.
    Vreugdenhil, Gerard
    Wouters, Michel W. J. M.
    van der Hoeven, Jacobus J. M.
    [J]. MELANOMA RESEARCH, 2018, 28 (04) : 326 - 332
  • [2] LONG-TERM CLINICAL OUTCOMES ASSOCIATED WITH SEQUENTIAL TREATMENT OF BRAF MUTANT ADVANCED MELANOMA PATIENTS
    Tarhini, Ahmad
    McDermott, David
    Ambavane, Apoorva
    Benedict, Agnes
    Lee, Cho-Han
    Ritchings, Corey
    Stwalley, Brian
    Regan, Meredith
    Atkins, Michael
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A130 - A131
  • [3] Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
    Karolina Piejko
    Bożena Cybulska-Stopa
    Marcin Ziętek
    Robert Dziura
    Łukasz Galus
    Natasza Kempa-Kamińska
    Barbara Ziółkowska
    Ewa Rutkowska
    Tomasz Kopciński
    Tomasz Kubiatowski
    Wiesław Bal
    Rafał Suwiński
    Jacek Mackiewicz
    Grażyna Kamińska-Winciorek
    Anna M. Czarnecka
    Piotr Rutkowski
    [J]. Targeted Oncology, 2023, 18 : 235 - 245
  • [4] Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy
    Atkins, Michael B.
    Julian, Cristina
    Secrest, Matthew H.
    Lee, Janet
    Abajo-Guijarro, Ana M.
    McKenna, Edward
    [J]. FUTURE ONCOLOGY, 2022, 18 (18) : 2233 - 2245
  • [5] Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
    Tarhini, Ahmad
    McDermott, David
    Ambavane, Apoorva
    Gupte-Singh, Komal
    Aponte-Ribero, Valerie
    Ritchings, Corey
    Benedict, Agnes
    Rao, Sumati
    Regan, Meredith M.
    Atkins, Michael
    [J]. IMMUNOTHERAPY, 2019, 11 (04) : 283 - 295
  • [6] Survival in BRAF-mutant metastatic melanoma in the real-world setting: results from the Dutch Melanoma Treatment Registry
    Schouwenburg, M.
    Jochems, A.
    Aarts, M.
    van den Berkmortel, F.
    van den Eertwegh, A.
    Franken, M.
    Groenewegen, G.
    de Groot, J-W.
    Haanen, J. B. A. G.
    Hospers, G.
    Kapiteijn, E.
    Koornstra, R.
    Kruit, W.
    Louwman, M.
    Piersma, D.
    van Rijn, R.
    Ten Tije, A. J.
    Vreugdenhil, G.
    Wouters, M.
    van der Hoeven, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Long-term survival of real-world advanced melanoma patients treated with targeted therapy
    Ismail, R.
    de Boer, A.
    van Dartel, M.
    Hilarius, D.
    van Zeijl, M.
    van den Eertwegh, F.
    Aarts, M.
    Van den Berkmortel, F.
    Boers-Sonderen, M.
    de Groot, J. W. B.
    Haanen, J. B. A. G.
    Hospers, G. A. P.
    Kapiteijn, E.
    Piersma, D.
    van Rijn, R.
    Suijkerbuijk, K. P. M.
    ten Tije, A. J.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Wouters, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S745 - S746
  • [8] Management of a Patient With Advanced BRAF-Mutant Melanoma
    Ashworth, Michelle T.
    Daud, Adil
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (03): : 315 - 319
  • [9] The perspectives and challenges in BRAF-mutant advanced melanoma
    Romanova, Alexandra
    Balandina, Anastasiia
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 45 - 45
  • [10] Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib plus Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
    Piejko, Karolina
    Cybulska-Stopa, Bozena
    Zietek, Marcin
    Dziura, Robert
    Galus, Lukasz
    Kempa-Kaminska, Natasza
    Ziolkowska, Barbara
    Rutkowska, Ewa
    Kopcinski, Tomasz
    Kubiatowski, Tomasz
    Bal, Wieslaw
    Suwinski, Rafal
    Mackiewicz, Jacek
    Kaminska-Winciorek, Grazyna
    Czarnecka, Anna M.
    Rutkowski, Piotr
    [J]. TARGETED ONCOLOGY, 2023, 18 (02) : 235 - 245
12345